Advocacy intelligence hub — real-time data for patient organizations
Leiden University Medical Center — NA
Lymphir: FDA approved
treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy
Targretin: FDA approved
Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs3
Targretin
Eisai, Inc.
Zolinza
Merck & Co., Inc.
Lymphir
Citius Oncology, Inc.
Lymphir
(denileukin diftitox-cxdl)Orphan drugCitius Oncology, Inc.
CD25-directed Cytotoxin [EPC]
12.1 Mechanism of Action Denileukin diftitox-cxdl is a fusion protein designed to direct the cytocidal action of diphtheria toxin (DT) to cells which ...
Targretin
(Bexarotene)Orphan drugEisai, Inc.
Retinoid [EPC]
12.1 Mechanism of Action Bexarotene selectively binds and activates retinoid X receptor subtypes (RXRα, RXRß, RXRγ). RXRs can form heterodimers with v...
Zolinza
(vorinostat)Orphan drugstandardMerck & Co., Inc.
Histone Deacetylase Inhibitor [EPC]
12.1 Mechanism of Action Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at n...
Istodax
(romidepsin)Orphan drugstandardCelgene Corporation
12.1 Mechanism of Action Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine resi...
Moderate-Dose Local Radiotherapy in Symptomatic CD30-Positive, Anaplastic Lymphoma Kinase (ALK)-Negative Primary Cutaneous T-cell Lymphoma.
Primary cutaneous anaplastic CD30-positive (+) T-cell lymphoma is a rare variant of primary cutaneous lymphoma characterized by proliferation of large T lymphocytes with strong CD30 expression and no ...
Hypopigmented CD8+ Mycosis Fungoides in Sri Lanka: Clinicopathologic Evidence for an Indolent Variant.
Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma and typically presents with erythematous or scaly patches in older adults with a CD4+ immunophenotype. In Sri Lanka, however...
Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor ® (Mechlorethamine) in the Treatment of CTCL.
Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell lymphoma (CTCL), a malignant and chronic skin disease. Early-stage MF has a generally favorable prognosis, but effective and ...
Molecular Markers Distinguishing Early-Stage Mycosis Fungoides From Atopic Dermatitis Skin Lesions.
Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell lymphoma, a disease characterized by malignant T cells that home to the skin. In early stages, clinical presentation is often...
T-cell receptor gamma (TRG) diversity predicts peripheral blood involvement in primary cutaneous T-cell lymphoma.
T-cell receptor gamma (TRG) diversity predicts peripheral blood involvement in primary cutaneous T-cell lymphoma.
Radiotherapy dose-response of mycosis fungoides with large cell transformation.
Mycosis fungoides (MF) is the most prevalent subtype of primary cutaneous T-cell lymphoma. Large cell transformation of MF (LCTMF) is rare and confers a poor prognosis. Radiotherapy (RT) is an effecti...
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Robert J Kreitman, M.D., MP
National Cancer Institute (NCI)
📍 OLNEY, MD
Tarsheen Sethi, MD, MD, MSCI
Yale University
📍 NEW HAVEN, CT
Madeleine Duvic, MD, M.D
UT MD Anderson Cancer Center
📍 HOUSTON, TX
Paul Martin
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Karen Syrjala
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 SEATTLE, WA